<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165734</url>
  </required_header>
  <id_info>
    <org_study_id>PAC203/PAC303</org_study_id>
    <secondary_id>PAC303</secondary_id>
    <nct_id>NCT03165734</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis</brief_title>
  <acronym>PACIFICA</acronym>
  <official_title>A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count &lt;50,000/μL)(PACIFICA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PSI CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CTI BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID
      of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe
      thrombocytopenia (platelet count &lt;50,000/μL). Approximately 348 patients in total will be
      enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P/C therapy
      (approximately 116 patients)

      Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/
      Post-essential Thrombocythemia Myelofibrosis

      Intervention/treatment: Drug-Pacritinib
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, controlled phase 3 study comparing the efficacy of pacritinib with
      P/C therapy in patients with PMF, PPV-MF, or PET-MF (Dynamic International Prognostic Scoring
      System [DIPSS] risk score of Intermediate-1 to High-Risk), who have had had no or limited
      exposure to any JAK2 inhibitor or are JAK2 inhibitor-naive, and who have severe
      thrombocytopenia (platelet count &lt;50,000/µL). This study was designed to use the pacritinib
      200 mg BID dose, which was determined to be the optimal dose based on dose- and
      exposure-response analyses conducted using all available data, including the dosing data from
      the previous portion of this study. Patients will be randomized 2:1 to receive pacritinib 200
      mg BID or the P/C therapy (limited to single drugs from the following list: corticosteroids,
      hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must
      be selected prior to randomization. Randomization will be stratified by prior JAK2 inhibitor
      therapy (yes/no) and P/C therapy selected prior to randomization. Prior JAK2 inhibitor
      therapy will be defined as any duration of treatment with a JAK2 inhibitor, such as
      ruxolitinib, fedratinib, or momelotinib. To be eligible, patients are not allowed to have
      been treated with more than one JAK2 inhibitor. Assigned treatment will continue until the
      patient experiences progressive disease or intolerable AEs, withdraws consent, or initiates
      new MF-directed therapy. No study treatment crossover will be allowed at any time. All
      patients should complete all visit procedures through Week 24, including patients who stop
      treatment or have protocol-defined progressive disease prior to Week 24, unless the patient
      withdraws consent for study procedures, dies, undergoes splenic irradiation or splenectomy,
      initiates any non-protocol-directed anti-MF treatment, or the study is terminated. In
      addition to the above, patients will be considered to have discontinued treatment if
      pacritinib or P/C therapy is held for &gt;28 consecutive days due to treatment toxicity, or if
      treatment is discontinued for lack of efficacy, or at the request of the principal
      investigator or the patient. Following the Week 24 assessment, patients who are benefiting
      from therapy will be allowed to continue receiving the assigned treatment (pacritinib or P/C)
      until the patient experiences progressive disease, intolerable AEs, withdraws consent, or
      initiates new MF-directed therapy. All randomized patients will be followed for survival for
      2.5 years from the date of randomization unless consent for follow-up is withdrawn.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">December 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spleen volume</measure>
    <time_frame>From baseline to 24 weeks</time_frame>
    <description>To compare the efficacy of pacritinib with that of physician's choice (P/C) therapy, as assessed by the proportion of patients achieving a ≥35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score (TSS)</measure>
    <time_frame>Between baseline and Week 24</time_frame>
    <description>To compare the efficacy of pacritinib with P/C therapy, as assessed by the proportion of patients achieving a ≥50% reduction in Total Symptom Score (TSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>until 2.5 years after the date of randomization</time_frame>
    <description>To compare the overall survival (OS) of patients treated with pacritinib versus those treated with P/C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) assessed at Week 24</measure>
    <time_frame>End of Week 12 to 2 years following Week 24 visit</time_frame>
    <description>To compare the percentage of patients who self-assess as &quot;very much improved&quot; or &quot;much improved&quot; as measured by the Patient Global Impression of Change (PGIC) in patients treated with pacritinib versus those treated with P/C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the safety of pacritinib versus P/C therapy</measure>
    <time_frame>Randomization through 30 after last treatment</time_frame>
    <description>Safety will be assessed based on the incidence and severity (according to the Common Terminology Criteria for Adverse Events) of treatment emergent adverse events from the time of randomization until 30 days after completion of treatment with pacritinib and/or physician's choice therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SVR of ≥35%</measure>
    <time_frame>Up to 24 Weeks</time_frame>
    <description>Time to achievement of SVR of ≥35%</description>
  </other_outcome>
  <other_outcome>
    <measure>Best response in SVR</measure>
    <time_frame>At 24 Weeks</time_frame>
    <description>Best response in SVR by MRI or CT scan</description>
  </other_outcome>
  <other_outcome>
    <measure>&gt;25% SVR</measure>
    <time_frame>Between baseline and Week 24</time_frame>
    <description>Proportion of patients achieving &gt;25% SVR</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell (RBC)</measure>
    <time_frame>Baseline to End of Treatment</time_frame>
    <description>Achievement of red blood cell (RBC) transfusion independence at Weeks 12 and 24</description>
  </other_outcome>
  <other_outcome>
    <measure>hemoglobin level</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>Improvement in hemoglobin level without transfusion at Weeks 12 and 24</description>
  </other_outcome>
  <other_outcome>
    <measure>platelet count</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>Improvement in platelet count at Weeks 12 and 24</description>
  </other_outcome>
  <other_outcome>
    <measure>platelet transfusions</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>Frequency of platelet transfusions at Weeks 12 and 24</description>
  </other_outcome>
  <other_outcome>
    <measure>PROMIS</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Improvement in fatigue as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) v.1.0 - Fatigue from Baseline through Week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Leukemia-free survival (LFS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Leukemia-free survival (LFS) of patients treated with pacritinib versus P/C therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of red blood cell transfusion-independent patients achieving a 1 g/dL and a 2 g/dL increase in hemoglobin</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The percentage of red blood cell transfusion-independent patients at baseline achieving a 1 g/dL and a 2 g/dL increase in hemoglobin at week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of platelet transfusion-independent patients with improvement in grade of thrombocytopenia</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The percentage of platelet transfusion-independent patients at baseline with improvement in grade of thrombocytopenia at week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of transfusion-dependent patients achieving transfusion independence and achieving 50% reduction in transfusion rate</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>The percentage of transfusion-dependent patients at baseline achieving transfusion independence and achieving 50% reduction in transfusion rate at week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemaglobin A1c</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Changes in hemoglobin A1c</description>
  </other_outcome>
  <other_outcome>
    <measure>mutated allelic burden, gene expression, and pharmacodynamic (PD) biomarkers</measure>
    <time_frame>Baseline to up to 24 Weeks</time_frame>
    <description>Changes in mutated allelic burden, gene expression, and pharmacodynamic (PD) biomarkers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-polycythemia Vera Myelofibrosis</condition>
  <condition>Post-essential Thrombocythemia Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Pacritinib 200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Choice (P/C) therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base</description>
    <arm_group_label>Pacritinib 200 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's Choice medications</intervention_name>
    <description>Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.</description>
    <arm_group_label>Physician's Choice (P/C) therapy</arm_group_label>
    <other_name>corticosteroids</other_name>
    <other_name>hydroxyurea</other_name>
    <other_name>danazol</other_name>
    <other_name>low-dose ruxolitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Diagnosis and Inclusion Criteria

          1. PMF, PPV-MF, or PET-MF (Tefferi and Vandiman 2008)

          2. Average platelet count of &lt;50,000/µL at Screening (Day -35 to Day -3) based on two
             measurements taken on different days; both measurements must be &lt;50,000/µL

          3. DIPSS Intermediate-1, Intermediate-2, or High risk (Passamonti et al 2010)

          4. Palpable splenomegaly ≥5 cm below the lower costal margin (LCM) in the midclavicular
             line as assessed by physical examination

          5. TSS of ≥10 on the MPN-SAF TSS 2.0 or a single symptom score of ≥5 or two symptoms of
             ≥3, including only the symptoms of left upper quadrant pain, bone pain, itching, or
             night sweats

          6. If the patient has received prior JAK2 inhibitor treatment, this treatment must meet
             at least one of the following criteria:

               1. Prior treatment with any JAK2 inhibitor, irrespective of dose, with a duration of
                  90 days or less. The 90-day period starts on the date of first administration of
                  JAK2 inhibitor therapy and continues for 90 calendar days, regardless of whether
                  therapy is administered continuously or intermittently during that interval.

               2. Prior treatment with ruxolitinib, at no more than 10 mg total daily dose on any
                  day, with a duration of 180 days or less. The 180-day period starts on the date
                  of first ruxolitinib administration and continues for 180 calendar days,
                  regardless of whether therapy is administered continuously or intermittently
                  during that interval.The patient may not have received &gt;10 mg of ruxolitinib on
                  any day during that interval

          7. Age ≥18 years

          8. Eastern Cooperative Oncology Group performance status 0 to 2

          9. Peripheral blast count of &lt;10% throughout the Screening period and at baseline

         10. Absolute neutrophil count of ≥500/µL

         11. Left ventricular cardiac ejection fraction of ≥50% by echocardiogram or multigated
             acquisition (MUGA) scan

         12. Adequate liver and renal function, defined by liver transaminases (aspartate
             aminotransferase [AST]/serum glutamic-oxaloacetic transaminase [SGOT] and alanine
             aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]) ≤3 × the upper
             limit of normal (ULN) (AST/ALT ≤5 × ULN if transaminase elevation is related to MF),
             direct bilirubin ≤4 × ULN, and creatinine ≤2.5 mg/dL

         13. Adequate coagulation defined by prothrombin time/international normalized ratio and
             partial thromboplastin time ≤1.5 × ULN

         14. If fertile, willing to use effective birth control methods during the study

         15. Willing to undergo and able to tolerate frequent MRI or CT scan assessments during the
             study

         16. Able to understand and willing to complete symptom assessments using a
             patient-reported outcome instrument

         17. Provision of signed informed consent

        Exclusion Criteria

          1. Life expectancy &lt;6 months

          2. Completed allogeneic stem cell transplant (allo-SCT) or are eligible for and willing
             to complete other approved available therapy including allo-SCT

          3. History of splenectomy or planning to undergo splenectomy

          4. Splenic irradiation within the last 6 months

          5. Previously treated with pacritinib

          6. Treatment with any MF-directed therapy within 14 days prior to treatment Day 1

          7. Any prior treatment with more than one JAK2 inhibitor

          8. Treatment with an experimental therapy within 28 days prior to treatment Day 1

          9. Systemic treatment with a strong CYP3A4 inhibitor or a strong cytochrome P450 (CYP450)
             inducer within 14 days prior to treatment Day 1. Shorter washout periods may be
             permitted with approval of the Medical Monitor, provided that the washout period is at
             least five half-lives of the drug prior to treatment Day 1

         10. Significant recent bleeding history defined as National Cancer Institute Common
             Terminology Criteria for Adverse Events (CTCAE) grade ≥2 within 3 months prior to
             treatment Day 1, unless precipitated by an inciting event (e.g., surgery, trauma, or
             injury)

         11. Systemic treatment with medications that increase the risk of bleeding, including
             anticoagulants, antiplatelet agents (except for aspirin dosages of ≤100 mg per day),
             anti-vascular endothelial growth factor (anti-vascular endothelial growth factor
             [anti-VEGF]) agents, and daily use of cyclooxygenase-1 (COX-1) inhibiting nonsteroidal
             anti- inflammatory drugs (NSAIDs) within 14 days prior to treatment Day 1

         12. Systemic treatment with medications that can prolong the QT interval within 14 days
             prior to treatment Day 1. Shorter washout periods may be permitted with approval of
             the Medical Monitor, provided that the washout period is at least five half-lives of
             the drug prior to treatment Day 1

         13. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within 6 months prior
             to treatment Day 1. Patients with asymptomatic grade 2 non- dysrhythmia cardiovascular
             conditions may be considered for inclusion, with the approval of the Medical Monitor,
             if stable and unlikely to affect patient safety.

         14. Any history of CTCAE grade ≥2 cardiac dysrhythmias within 6 months prior to treatment
             Day 1. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for
             inclusion, with the approval of the Medical Monitor, if the dysrhythmias are stable,
             asymptomatic, and unlikely to affect patient safety.

         15. QT corrected by the Fridericia method (QTcF) prolongation &gt;450 ms or other factors
             that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia
             [defined as serum potassium &lt;3.0 mEq/L that is persistent and refractory to
             correction], or history of long QT interval syndrome

         16. New York Heart Association Class II, III, or IV congestive heart failure

         17. Any active gastrointestinal or metabolic condition that could interfere with
             absorption of oral medication

         18. Active or uncontrolled inflammatory or chronic functional bowel disorder such as
             Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation

         19. Other malignancy within 3 years prior to treatment Day 1, other than curatively
             treated basal cell or squamous cell skin or corneal cancer; curatively treated
             carcinoma in situ of the cervix; organ-confined prostate cancer with prostate-specific
             antigen (PSA) &lt;20 ng/mL and National Comprehensive Cancer Network risk of Very Low,
             Low, or Favorable Intermediate; curatively treated non-metastatic prostate cancer with
             negative PSA; or in situ breast carcinoma after complete surgical resection

         20. Uncontrolled intercurrent illness, including, but not limited to, ongoing active
             infection, psychiatric illness, or social situation that, in the judgment of the
             treating physician, would limit compliance with study requirements

         21. Known seropositivity for human immunodeficiency virus

         22. Known active hepatitis A, B, or C virus infection

         23. Women who are pregnant or lactating

         24. Concurrent enrollment in another interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simran Bedi Singh</last_name>
    <role>Study Director</role>
    <affiliation>CTI BioPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simran Bedi Singh, MD</last_name>
    <phone>206-272-4454</phone>
    <email>ssingh@ctibiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Volpone</last_name>
    <phone>1-206-272-4652</phone>
    <email>jvolpone@ctibiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-975-7162</phone>
      <email>tdcole@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron Vanderlinden</last_name>
      <phone>480-342-6065</phone>
      <email>Vanderlinden.Cameron@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>626-256-4973</phone>
      <phone_ext>82312</phone_ext>
      <email>eriffle@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Duran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>310-794-7538</phone>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers (US Oncology/McKesson)</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie Donnachaidh</last_name>
      <phone>303-388-4876</phone>
      <email>bobbie.donnachaidh@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra dormal</last_name>
      <phone>203-785-4699</phone>
      <email>Alexandra.dormal@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Washington University-Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <phone>202-741-2210</phone>
      <email>toukie@email.gwu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pyone Lwin Maung</last_name>
      <phone>312-695-1324</phone>
      <email>pyone.maung@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center and Medical Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>913-588-8693</phone>
      <email>lvu4@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>667-234-2966</phone>
      <email>chopmann@ascension.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC - CCBD Division</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine Hematology Clinic-Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>734-232-4312</phone>
      <email>lfarhat@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine-Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Gordon</last_name>
      <phone>314-362-0156</phone>
      <email>kdgordon@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>551-996-8137</phone>
      <email>Michelle.Borza@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-305-2696</phone>
      <email>pg2669@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>212-824-7313</phone>
      <email>devin.jones@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan -Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coodinator</last_name>
      <phone>646-608-2767</phone>
      <email>ryana2@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Rollinson</last_name>
      <phone>585-276-3051</phone>
      <email>Sarah_Rollinson@URMC.Rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coodinator</last_name>
      <phone>216-444-3576</phone>
      <email>rootk2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Long</last_name>
      <phone>614-688-9497</phone>
      <email>Lauren.Long@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-2055</phone>
      <email>yap@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Feki</last_name>
      <phone>412-623-7302</phone>
      <email>fekim@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute-Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niki Garrett</last_name>
      <phone>615-524-4097</phone>
      <email>Niki.Garrett@SarahCannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coordinator</last_name>
      <phone>713-563-2622</phone>
      <email>KDSchroe@MDAnderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Center at San Antonio School of Medicine</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Grimm</last_name>
      <phone>206-667-2353</phone>
      <email>lgrimm@fredhutch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Research Center for Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grodno University Hospital</name>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center, Internal Medicine/Hematology</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Hematology - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzen</name>
      <address>
        <city>Pilsen</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady, Clinic of Internal Hematology</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Amiens Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes - Hopital Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautepierre Hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Toulouse- Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC K. Eristavi National Center For Experimental and Clinical Surgery</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD M.Zodelava's Hematology Center, Department of Hematology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD S.Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LTD</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne, Department of Internal Medicine I,</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Hospital Minden, Department of Oncology and Hematology</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital rechts der Isar, Department of Internal Medicine III, Hematology and Oncology</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm, Center for Internal Medicine,</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University SE ÁOK I. sz. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Clinical Center (Debreceni Egyetem Klinikai Központ)</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun County Hospital, 2nd Department of Internal Medicine</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center, Department of Hematology,</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center, Department of Hematology,</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Clinic for Myeloproliferative Disorders</name>
      <address>
        <city>Petah-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center, Department of Internal Medicine</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Institute &quot;Giovanni Paolo II&quot;, IRCCS</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinic S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST), IRCCS</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Monza - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>United Hospitals Villa Sofia Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinic San Matteo, IRCCS</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Polyclinic Foundation &quot;Agostino Gemelli&quot;</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi Hospital</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center in Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital in Krakow</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frederic Chopin Provincial Teaching Hospital No. 1 in Rzeszow, Department of Hematology,</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusion Medicine, Teaching Department of Hematology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jan Mikulicz Radecki University Hospital in Wroclaw, Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Provincial Multispecialty Oncology and Traumatology Center in Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #40</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #81</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.P. Botkin City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic UZI 4D, LLC</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.M. Kirov Military Medical Academy, Department and Clinic for Intermediate-Level Training in Internal Medicine, Hematology Division</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>V.A. Almazov North-West Federal Medical Research Center, Institute of Oncology and Hematology, Scientific Department of Clinical Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>V.D. Seredavin Samara Regional Clinical Hospital, Department of Hematology</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia, Clinic of Hematology</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina, Clinic of Hematology</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona,</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morales Meseguer University General Hospital, Department of Hematology and Hemotherapy</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Salamanca, Department of Hematology</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Dispensary of Cherkasy Oblast Council, Regional Treatment and Diagnostic Hematology Center, Department of Hematology</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital, Department of Hematology,</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit enterprise &quot;Regional Center of Oncology&quot;, Department of Hematology</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #9, Hematology Department #1</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv Regional Oncology Center, Department of Hematology,</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital, Department of Hematology</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust - The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust - Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelofibrosis</keyword>
  <keyword>pacritinib</keyword>
  <keyword>Post-polycythemia Vera Myelofibrosis</keyword>
  <keyword>Post-essential Thrombocythemia Myelofibrosis</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>Bone Marrow Disease</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Blood Platelet Disorders</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Splenomegaly</keyword>
  <keyword>Anemia</keyword>
  <keyword>Spleen volume</keyword>
  <keyword>Spleen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

